Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Recombinant FVIIa in the management of uncontrolled hemorrhage.

O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP.

Transfusion. 2003 Dec;43(12):1711-6.

PMID:
14641868
2.

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Pediatr Hematol Oncol. 2008 Jun;25(4):301-11. doi: 10.1080/08880010802016904.

PMID:
18484474
3.

A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes.

MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M.

Transfusion. 2005 Sep;45(9):1434-42.

PMID:
16131375
4.

Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.

Bowman LJ, Uber WE, Stroud MR, Christiansen LR, Lazarchick J, Crumbley AJ 3rd, Kratz JM, Toole JM, Crawford FA Jr, Ikonomidis JS.

Ann Thorac Surg. 2008 May;85(5):1669-76; discussion 1676-7. doi: 10.1016/j.athoracsur.2008.01.089.

PMID:
18442563
5.

Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.

Brandsborg S, Sørensen B, Poulsen LH, Ingerslev J.

Blood Coagul Fibrinolysis. 2006 Jun;17(4):241-9.

PMID:
16651865
6.

Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.

Razon Y, Erez E, Vidne B, Birk E, Katz J, Tamari H, Dagan O.

Paediatr Anaesth. 2005 Mar;15(3):235-40.

PMID:
15725322
7.

Efficacy of recombinant activated Factor VII in patients with massive uncontrolled bleeding: a retrospective observational analysis.

Berkhof FF, Eikenboom JC.

Transfusion. 2009 Mar;49(3):570-7. doi: 10.1111/j.1537-2995.2008.02001.x. Epub 2008 Nov 25.

PMID:
19040498
8.

Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.

Dunkley S, Phillips L, McCall P, Brereton J, Lindeman R, Jankelowitz G, Cameron P.

Ann Thorac Surg. 2008 Mar;85(3):836-44. doi: 10.1016/j.athoracsur.2007.06.076.

PMID:
18291152
9.

Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.

Chuansumrit A, Isarangkura P, Angchaisuksiri P, Sriudomporn N, Tanpowpong K, Hathirat P, Jorgensen LN.

Haemophilia. 2000 Mar;6(2):61-5.

PMID:
10781189
10.

Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery.

Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, Sellke F, Booth F, Schmidt TA.

Circulation. 2009 Jul 7;120(1):21-7. doi: 10.1161/CIRCULATIONAHA.108.834275. Epub 2009 Jun 22.

11.

Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.

Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y; NovoSeven Trauma Study Group.

J Trauma. 2005 Jul;59(1):8-15; discussion 15-8.

PMID:
16096533
12.

Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experience.

Karsies TJ, Nicol KK, Galantowicz ME, Stephens JA, Kerlin BA.

Ann Thorac Surg. 2010 Feb;89(2):570-6. doi: 10.1016/j.athoracsur.2009.11.023.

PMID:
20103344
13.

A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage.

Franchini M, Franchi M, Bergamini V, Salvagno GL, Montagnana M, Lippi G.

Semin Thromb Hemost. 2008 Feb;34(1):104-12. doi: 10.1055/s-2008-1066022. Review.

PMID:
18393147
14.

Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.

Brady KM, Easley RB, Tobias JD.

Paediatr Anaesth. 2006 Oct;16(10):1042-6.

PMID:
16972833
15.

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Am J Hematol. 2002 Mar;69(3):219-22.

PMID:
11891811
16.

Recombinant activated factor VII in controlling bleeding in non-hemophiliac patients.

AlGahtani FH, Alshaikh M, AlDiab A.

Ann Saudi Med. 2010 May-Jun;30(3):198-202. doi: 10.4103/0256-4947.62830.

17.

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.

Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM.

J Thromb Haemost. 2006 Feb;4(2):367-71.

18.

Complications of recombinant activated human coagulation factor VII.

Howes JL, Smith RS, Helmer SD, Taylor SM.

Am J Surg. 2009 Dec;198(6):895-9. doi: 10.1016/j.amjsurg.2009.05.026.

PMID:
19969148
19.

Use of recombinant activated factor VII to control bleeding in a young child with qualitative platelet disorder: a case report.

Inagaki M, Mori T, Tsunematsu Y, Ambo H, Kawai Y.

Blood Coagul Fibrinolysis. 2006 Jun;17(4):317-22.

PMID:
16651876
20.

Safety of recombinant activated factor VII in randomized clinical trials.

Levi M, Levy JH, Andersen HF, Truloff D.

N Engl J Med. 2010 Nov 4;363(19):1791-800. doi: 10.1056/NEJMoa1006221. Erratum in: N Engl J Med. 2011 Nov 17;365(20):1944.

Supplemental Content

Support Center